Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TranspoCART19 in refractory lupus nephritis (Phase I–IIa, Spain)
2025-522449-23-00Phase 2Authorised
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Sep 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TranspoCART19 in lupus nephritis (LN) and systemic lupus erythematosus (SLE), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: Primary safety and tolerability endpoint (Day 0–28, up to Day 42). Planned start Sep 2026; status: authorised.
02
Drugs
TranspoCART19
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2025-522449-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522449-23-00.